Movement Alert｜CANSINOBIO Rises 5.12% in Regular Trading, Biotech Sector Strengthens Ahead of Upcoming Earnings Briefing

Market Focus

Sep 14

On September 14, CANSINOBIO rose 5.12% in regular trading, trading at 27.2 HKD/share, with turnover of approximately 48.59 million HKD.

The rise was driven by broad-based strength in the biotech sector combined with an upcoming catalyst: the company is scheduled to participate in a STAR Market semi-annual biologics and CXO industry earnings briefing on September 15, where management will discuss operational and financial results with investors. Within the sector, AKESO gained 5.32%, Everest Medicines rose 4.10%, and BEONE Medicines climbed 1.75%.

The company's previously disclosed interim report showed H1 revenue of RMB 5.50 billion, up 43.81% year-over-year, while overseas revenue surged 4,724.19% to RMB 1.52 billion. Net loss attributable to shareholders narrowed dramatically to just RMB 720,800. Recent catalysts also include the signing of an mRNA personalized therapeutic cancer vaccine strategic cooperation agreement, approval of its tetanus vaccine by China's NMPA, and acceptance of its Td5cp vaccine NDA filing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/news/1162924395"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162924395\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162924395?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 10:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162924395","market":"us","top_or_hot":-1,"title":"Movement Alert｜CANSINOBIO Rises 5.12% in Regular Trading, Biotech Sector Strengthens Ahead of Upcoming Earnings Briefing","media":"Market Focus","content":"<p><p>On September 14, CANSINOBIO rose 5.12% in regular trading, trading at 27.2 HKD/share, with turnover of approximately 48.59 million HKD.</p><p>The rise was driven by broad-based strength in the biotech sector combined with an upcoming catalyst: the company is scheduled to participate in a STAR Market semi-annual biologics and CXO industry earnings briefing on September 15, where management will discuss operational and financial results with investors. Within the sector, AKESO gained 5.32%, Everest Medicines rose 4.10%, and BEONE Medicines climbed 1.75%.</p><p>The company's previously disclosed interim report showed H1 revenue of RMB 5.50 billion, up 43.81% year-over-year, while overseas revenue surged 4,724.19% to RMB 1.52 billion. Net loss attributable to shareholders narrowed dramatically to just RMB 720,800. Recent catalysts also include the signing of an mRNA personalized therapeutic cancer vaccine strategic cooperation agreement, approval of its tetanus vaccine by China's NMPA, and acceptance of its Td5cp vaccine NDA filing.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CANSINOBIO Rises 5.12% in Regular Trading, Biotech Sector Strengthens Ahead of Upcoming Earnings Briefing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CANSINOBIO Rises 5.12% in Regular Trading, Biotech Sector Strengthens Ahead of Upcoming Earnings Briefing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-14 10:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 14, CANSINOBIO rose 5.12% in regular trading, trading at 27.2 HKD/share, with turnover of approximately 48.59 million HKD.</p><p>The rise was driven by broad-based strength in the biotech sector combined with an upcoming catalyst: the company is scheduled to participate in a STAR Market semi-annual biologics and CXO industry earnings briefing on September 15, where management will discuss operational and financial results with investors. Within the sector, AKESO gained 5.32%, Everest Medicines rose 4.10%, and BEONE Medicines climbed 1.75%.</p><p>The company's previously disclosed interim report showed H1 revenue of RMB 5.50 billion, up 43.81% year-over-year, while overseas revenue surged 4,724.19% to RMB 1.52 billion. Net loss attributable to shareholders narrowed dramatically to just RMB 720,800. Recent catalysts also include the signing of an mRNA personalized therapeutic cancer vaccine strategic cooperation agreement, approval of its tetanus vaccine by China's NMPA, and acceptance of its Td5cp vaccine NDA filing.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06185","symbol_name":"康希诺生物","start_time":0,"source_url":"","article_id":"1162924395","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162924395","pubTimestamp":1789353274,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 14, CANSINOBIO rose 5.12% in regular trading, trading at 27.2 HKD/share, with turnover of approximately 48.59 million HKD.The rise was driven by broad-based strength in the biotech...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06185":"康希诺生物"},"translate_title":"走势警报|康希诺生物在常规交易中上涨 5.12%，生物技术板块在即将召开的财报发布会前走强","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"On September 14, CANSINOBIO rose 5.12% in regular trading, trading at 27.2 HKD/share, with turnover of approximately 48.59 million HKD.The rise was driven by broad-based strength in the biotech sector combined with an upcoming catalyst: the company is scheduled to participate in a STAR Market semi-annual biologics and CXO industry earnings briefing on September 15, where management will discuss operational and financial results with investors. Within the sector, AKESO gained 5.32%, Everest Medicines rose 4.10%, and BEONE Medicines climbed 1.75%.The company's previously disclosed interim report showed H1 revenue of RMB 5.50 billion, up 43.81% year-over-year, while overseas revenue surged 4,724.19% to RMB 1.52 billion. Net loss attributable to shareholders narrowed dramatically to just RMB 720,800. Recent catalysts also include the signing of an mRNA personalized therapeutic cancer vaccine strategic cooperation agreement, approval of its tetanus vaccine by China's NMPA, and acceptance of its Td5cp vaccine NDA filing.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}